Antibody‐ and aptamer‐strategies for Gv HD prevention

Prevention of Graft‐ versus ‐Host‐Disease (Gv HD ) by preserved Graft‐ versus ‐Leukaemia (GvL) effect is one of the major obstacles following allogeneic haematopoietic stem cell transplantation. Currently used drugs are associated with side effects and were not able to separate Gv HD from the GvL‐ef...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular and molecular medicine 2015-01, Vol.19 (1), p.11-20
Main Authors: Oelkrug, Christopher, Sack, Ulrich, Boldt, Andreas, Nascimento, Isis C., Ulrich, Henning, Fricke, Stephan
Format: Article
Language:English
Subjects:
Animal models
Antigens
Aptamers
Bone marrow
Chemotherapy
Disease
Graft-versus-host reaction
Hematology
Hematopoietic stem cells
Immune response
Immune system
Immunoglobulins
Immunology
Immunosuppressive agents
Leukemia
Ligands
Liver
Lymphocytes
Mortality
Radiation therapy
Side effects
Stem cells
Transplantation
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prevention of Graft‐ versus ‐Host‐Disease (Gv HD ) by preserved Graft‐ versus ‐Leukaemia (GvL) effect is one of the major obstacles following allogeneic haematopoietic stem cell transplantation. Currently used drugs are associated with side effects and were not able to separate Gv HD from the GvL‐effect because of general T‐cell suppression. This review focuses on murine models for Gv HD and currently available treatment options involving antibodies and applications for the therapeutic use of aptamers as well as strategies for targeting immune responses by allogenic antigens.
ISSN:1582-1838
1582-4934
DOI:10.1111/jcmm.12416